Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma : The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial
Importance: Patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC) have a poor prognosis and few therapeutic options. Preclinical studies support targeting PI3K/AKT/mTOR signaling in this setting, and a phase 1 study of the dual mTORC1/mTORC2 inhibitor vistusertib with weekly paclitaxel showed activity.
Objective: To evaluate whether the addition of vistusertib to weekly paclitaxel improves clinical outcomes in patients with PR-HGSC.
Design, Setting, and Participants: This phase 2, double-blind, placebo-controlled multicenter randomized clinical trial recruited patients from UK cancer centers between January 2016 and March 2018. Patients with PR-HGSC of ovarian, fallopian tube, or primary peritoneal origin and with measurable or evaluable disease (Response Evaluation Criteria in Solid Tumors version 1.1 and/or Gynecological Cancer Intergroup cancer antigen 125 criteria) were eligible. There were no restrictions on number of lines of prior therapy. Data analysis was performed from May 2019 to January 2022.
Interventions: Patients were randomized (1:1) to weekly paclitaxel (80 mg/m2 days 1, 8, and 15 of a 28-day cycle) plus oral vistusertib (50 mg twice daily) or placebo.
Main Outcomes and Measures: The primary end point was progression-free survival in the intention-to-treat population. Secondary end points included response rate, overall survival, and quality of life.
Results: A total of 140 patients (median [range] age, 63 [36-86] years; 17.9% with platinum-refractory disease; 53.6% with ≥3 prior therapies) were randomized. In the paclitaxel plus vistusertib vs paclitaxel plus placebo groups, there was no difference in progression-free survival (median, 4.5 vs 4.1 months; hazard ratio [HR], 0.84; 80% CI, 0.67-1.07; 1-sided P = .18), overall survival (median, 9.7 vs 11.1 months; HR, 1.21; 80% CI, 0.91-1.60) or response rate (odds ratio, 0.86; 80% CI, 0.55-1.36). Grade 3 to 4 adverse events were 41.2% (weekly paclitaxel plus vistusertib) vs 36.7% (weekly paclitaxel plus placebo), and there was no difference in quality of life.
Conclusions and Relevance: In this randomized clinical trial of weekly paclitaxel and dual mTORC1/2 inhibition in patients with PR-HGSC, vistusertib did not improve clinical activity of weekly paclitaxel.
Trial Registration: isrctn.org Identifier: ISRCTN16426935.
| Errataetall: |
ErratumIn: JAMA Oncol. 2023 Aug 1;9(8):1155. - PMID 37318796 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
JAMA oncology - 9(2023), 5 vom: 01. Mai, Seite 675-682 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Banerjee, Susana [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.05.2023 Date Revised 17.03.2024 published: Print ISRCTN: ISRCTN16426935 ErratumIn: JAMA Oncol. 2023 Aug 1;9(8):1155. - PMID 37318796 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamaoncol.2022.7966 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354337858 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354337858 | ||
| 003 | DE-627 | ||
| 005 | 20240317232909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamaoncol.2022.7966 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1333.xml |
| 035 | |a (DE-627)NLM354337858 | ||
| 035 | |a (NLM)36928279 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Banerjee, Susana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma |b The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.05.2023 | ||
| 500 | |a Date Revised 17.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ISRCTN: ISRCTN16426935 | ||
| 500 | |a ErratumIn: JAMA Oncol. 2023 Aug 1;9(8):1155. - PMID 37318796 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: Patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC) have a poor prognosis and few therapeutic options. Preclinical studies support targeting PI3K/AKT/mTOR signaling in this setting, and a phase 1 study of the dual mTORC1/mTORC2 inhibitor vistusertib with weekly paclitaxel showed activity | ||
| 520 | |a Objective: To evaluate whether the addition of vistusertib to weekly paclitaxel improves clinical outcomes in patients with PR-HGSC | ||
| 520 | |a Design, Setting, and Participants: This phase 2, double-blind, placebo-controlled multicenter randomized clinical trial recruited patients from UK cancer centers between January 2016 and March 2018. Patients with PR-HGSC of ovarian, fallopian tube, or primary peritoneal origin and with measurable or evaluable disease (Response Evaluation Criteria in Solid Tumors version 1.1 and/or Gynecological Cancer Intergroup cancer antigen 125 criteria) were eligible. There were no restrictions on number of lines of prior therapy. Data analysis was performed from May 2019 to January 2022 | ||
| 520 | |a Interventions: Patients were randomized (1:1) to weekly paclitaxel (80 mg/m2 days 1, 8, and 15 of a 28-day cycle) plus oral vistusertib (50 mg twice daily) or placebo | ||
| 520 | |a Main Outcomes and Measures: The primary end point was progression-free survival in the intention-to-treat population. Secondary end points included response rate, overall survival, and quality of life | ||
| 520 | |a Results: A total of 140 patients (median [range] age, 63 [36-86] years; 17.9% with platinum-refractory disease; 53.6% with ≥3 prior therapies) were randomized. In the paclitaxel plus vistusertib vs paclitaxel plus placebo groups, there was no difference in progression-free survival (median, 4.5 vs 4.1 months; hazard ratio [HR], 0.84; 80% CI, 0.67-1.07; 1-sided P = .18), overall survival (median, 9.7 vs 11.1 months; HR, 1.21; 80% CI, 0.91-1.60) or response rate (odds ratio, 0.86; 80% CI, 0.55-1.36). Grade 3 to 4 adverse events were 41.2% (weekly paclitaxel plus vistusertib) vs 36.7% (weekly paclitaxel plus placebo), and there was no difference in quality of life | ||
| 520 | |a Conclusions and Relevance: In this randomized clinical trial of weekly paclitaxel and dual mTORC1/2 inhibition in patients with PR-HGSC, vistusertib did not improve clinical activity of weekly paclitaxel | ||
| 520 | |a Trial Registration: isrctn.org Identifier: ISRCTN16426935 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Paclitaxel |2 NLM | |
| 650 | 7 | |a P88XT4IS4D |2 NLM | |
| 650 | 7 | |a vistusertib |2 NLM | |
| 650 | 7 | |a 0BSC3P4H5X |2 NLM | |
| 650 | 7 | |a Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a Mechanistic Target of Rapamycin Complex 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Giannone, Gaia |e verfasserin |4 aut | |
| 700 | 1 | |a Clamp, Andrew R |e verfasserin |4 aut | |
| 700 | 1 | |a Ennis, Darren P |e verfasserin |4 aut | |
| 700 | 1 | |a Glasspool, Rosalind M |e verfasserin |4 aut | |
| 700 | 1 | |a Herbertson, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Krell, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Riisnaes, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Mirza, Hasan B |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Zhao |e verfasserin |4 aut | |
| 700 | 1 | |a McDermott, Jacqueline |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Clare |e verfasserin |4 aut | |
| 700 | 1 | |a Kristeleit, Rebecca S |e verfasserin |4 aut | |
| 700 | 1 | |a George, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Gourley, Charlie |e verfasserin |4 aut | |
| 700 | 1 | |a Lewsley, Liz-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Rai, Debbie |e verfasserin |4 aut | |
| 700 | 1 | |a Banerji, Udai |e verfasserin |4 aut | |
| 700 | 1 | |a Hinsley, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a McNeish, Iain A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA oncology |d 2015 |g 9(2023), 5 vom: 01. Mai, Seite 675-682 |w (DE-627)NLM250070588 |x 2374-2445 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:5 |g day:01 |g month:05 |g pages:675-682 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamaoncol.2022.7966 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 5 |b 01 |c 05 |h 675-682 | ||